Topics

Sandra Anderson is Senior Vice President of Commercialization & Strategy at Innomar Strategies. With more than 20 years of pharmaceutical and clinical experience, she oversees a diverse team of 60 associates focused on regulatory, reimbursement, health economics, market access, business development, marketing, and stakeholder relations.

Articles

Sandra Anderson outlines what manufacturers need to know about the regulatory environment and commercialization solutions for the Canadian market.

Commercializing Cell and Gene Therapies in Canada

The benefits of establishing an in-depth go-to-market commercialization strategy for a new CGT in the beginning of clinical trials

Cell and gene therapy success: Overcoming patient and provider apprehension 

Taking cues from launches so far in oncology and rheumatology, three important considerations for biosimilar marketability are outlined

Key learnings to support biosimilar commercialization in the US

Focusing on key groups will drive the greatest impact in health outcomes

How pharma and HCPs can support backlogged pandemic patients

The biggest areas of adjustment in patient support brought on by changes in consumer and physician behavior

Five powerful Covid-related shifts in patient care

AI-driven strategies for pharma brand marketing teams to help bridge
the gap from data intelligence to execution

RWD Benefits at the Point of Care

How to best plan out and implement a marketing data hub as a key tool to harnessing today’s omnichannel transformation in pharma

Marketing Data Hubs: When Operations and Analytics Collide

Outlining the key digital trends accelerated by the transformed healthcare landscape in 2021—and their impact on pharma commercialization strategies going forward 

Why agility is the key to navigating the fast-changing healthcare landscape

How the development of more quantitative and qualitative data around the patient can drive better-informed care decisions—and help avoid potential overstock scenarios that can deplete earnings 

Effective patient-first approach in rare disease relies on true sales—not channel stocking 

How pharma’s retooling of its promotional efforts in the post-pandemic era impacts sizing and targeting, two crucial foundational pieces to successful commercialization

Commercial Channels